Sunil Healthcare's Q4 FY 2025-26 Quarterly Results

Result Summary

• Sunil Healthcare Ltd reported a 9.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 7.2%.
• Its expenses for the quarter were down by 2.5% QoQ and 2.1% YoY.
• The net profit increased 157.6% QoQ and increased 322.2% YoY.
• The earnings per share (EPS) of Sunil Healthcare Ltd stood at 1.48 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sunil Healthcare Ltd is a company that operates in the pharmaceutical and healthcare industry. It primarily focuses on the production of pharmaceutical capsules, catering to the needs of pharmaceutical companies both domestically and internationally. While specific recent major developments are not provided, Sunil Healthcare Ltd is known for its commitment to quality and innovation in capsule manufacturing. The company continues to seek growth opportunities in its core market segments. Any additional specific information on recent developments or strategic initiatives was not available at the time of this report.

Revenue

In the fourth quarter of the fiscal year 2026 (Q4FY26), Sunil Healthcare Ltd reported a total income of ₹20.13 crores. This reflects a quarter-over-quarter (QoQ) decrease of 9.9% compared to ₹22.33 crores in the previous quarter (Q3FY26). On a year-over-year (YoY) basis, the total income decreased by 7.2% from ₹21.69 crores in Q4FY25. The decline in revenue over these periods could be attributed to various market factors, though specific reasons are not detailed in the provided data.

Profitability

The company experienced a shift in profitability during Q4FY26, with a Profit Before Tax (PBT) of -₹0.95 crores, marking a significant decrease from a positive PBT of ₹0.84 crores in Q3FY26. Compared to Q4FY25, where the PBT was ₹0.28 crores, the change is even more pronounced. Despite the negative PBT in Q4FY26, the Profit After Tax (PAT) was reported at ₹1.52 crores, showing a substantial increase both QoQ (157.6%) and YoY (322.2%). This improvement is largely due to a tax credit of ₹2.46 crores, which reversed the negative PBT into a positive PAT. Earnings Per Share (EPS) also increased significantly, reaching ₹1.48 compared to ₹0.57 in Q3FY26 and ₹0.35 in Q4FY25.

Operating Metrics

The financial data indicates that total expenses for Sunil Healthcare Ltd in Q4FY26 were ₹20.96 crores, which is a 2.5% decrease from ₹21.50 crores in Q3FY26 and a 2.1% decrease from ₹21.41 crores in Q4FY25. The reduction in expenses suggests efficient cost management or operational adjustments during the quarter. The significant tax credit in Q4FY26 also had a noteworthy impact on the company's financial performance, contributing to the increase in PAT. The relationships between income, expenses, and tax considerations underscore the complexity of the operating environment the company navigated during this reporting period. Specific operating ratios such as the P/E ratio, debt-to-equity ratio, or current ratio were not provided, limiting further analysis of operational efficiency.